Cystic Fibrosis

October 16, 2015November 5, 2015

Galapagos Announces Advancement of Triple Combination Therapy into Development for Cystic Fibrosis Treatment

Cystic Fibrosis, News

Galapagos NV has announced the advancement of development plans for a triple combination Cystic fibrosis (CF) therapy consisting of GLPG2665, one of the multiple C2 correctors developed by the company, corrector ... Read more

October 12, 2015November 5, 2015

Vertex Presents Key Findings on Kalydeco, Orkambi & Experimental CF Therapies at NACFC

Cystic Fibrosis, News

A series of new updates and future development plans were recently announced by Vertex regarding its approved and candidate drugs to treat Cystic fibrosis (CF). The announcements, made at the 29th Annual ... Read more

October 8, 2015November 5, 2015

Nivalis Announces Positive Data of Phase 1b Study of Experimental Therapy N91115 in Cystic Fibrosis

Cystic Fibrosis, News

Nivalis Therapeutics, Inc., a pharmaceutical company focused on developing treatments for patients with cystic fibrosis (CF), recently announced positive topline data from its Phase 1b trial assessing N91115, an investigational ... Read more

October 6, 2015November 5, 2015

EMA Validates PTC Therapeutics’ Submission for New Nonsense Mutation Cystic Fibrosis Indication for Translarna (Ataluren)

Cystic Fibrosis, News

The European Medicines Agency (EMA) recently accepted a submission of variation for a new indication from PTC Therapeutics regarding Translarna (ataluren) for nonsense mutation cystic fibrosis (nmCF), which would allow the drug ... Read more

October 6, 2015November 5, 2015

Raptor Pharmaceutical Acquires Rights To Long-Term Treatment Quinsair For Lung Infections Common in CF Patients

Cystic Fibrosis, News

Raptor Pharmaceutical Corp., a global biopharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases, recently announced that it has acquired the ... Read more

October 5, 2015November 5, 2015

Anthera Pharmaceuticals Announces Start of Cystic Fibrosis Patient Recruitment For SOLUTION Clinical Trial

Cystic Fibrosis, News

Anthera Pharmaceuticals, Inc. announced that it is actively recruiting participants for its new Phase 3 clinical study on Cystic Fibrosis, called SOLUTION (Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin). ... Read more

October 1, 2015November 5, 2015

New Genome-wide Study Identifies Five Genetic Regions Involved in Cystic Fibrosis Disease Severity

Cystic Fibrosis, News

A new study, conducted by International CF Modifier Consortium and published in Nature Communications, reports the discovery of five regions of the human genome associated with cystic fibrosis (CF) severity. ... Read more

September 29, 2015November 5, 2015

Researchers Find No Particular Resistance to Antibiotics in Young Cystic Fibrosis Patients Infected By Non-pseudomonal Bacterial Species

Cystic Fibrosis, News

In a recently published paper in PeerJ journal entitled “Comparative genomics of non-pseudomonal bacterial species colonizing young cystic fibrosis patients,” researchers from Australia analyzed a series of non-pseudomonal strain isolates ... Read more

September 23, 2015November 5, 2015

Concert Pharma Reports Phase 1 Results of Experimental CF Therapy CTP-656

Cystic Fibrosis, News

Concert Pharma, a biotechnology company utilizing deuterium chemistry to discover and develop innovative drug products that can address unmet medical needs, recently announced positive results from its Phase 1 single ascending dose study ... Read more

September 18, 2015November 5, 2015

Arch Biopartners New Therapy Could Treat Infections With Resistant P. Aeruginosa in CF Patients

Cystic Fibrosis, News

On September 17th, 2015, Arch Biopartners Inc. announced that the drug AB569 designed to treat pulmonary infections with Pseudomonas aeruginosa (P. aeruginosa) completed successful pre-clinical in vitro and in vivo ... Read more